Reddy's, Eris Life sciences, and Natco Pharma are preparing to launch affordable generic versions, potentially reducing prices by 50-60%
Retatrutide is still in clinical trials and has not been approved by any medicines regulator anywhere in the world
Let's dissect the implications for competition, compliance risks, and where opportunities might lie
Clinical evidence (based on the literature) on GLP-1 RAs licensed in South Asia or under regulatory approval in one or more South Asian countries is presented and based on prescription pattern and the geography of the reported patient group
Injection-site reactions (redness, itching) occur in under 5% of users
Calibrates exercise approach focuses on prioritizing movement plus two sessions of strength training each week, making it a regular and positive part of the day